Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2005-05-17
2005-05-17
Lacourciere, Karen A. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S262100, C514S263100, C514S263200
Reexamination Certificate
active
06894021
ABSTRACT:
This invention concerns methods for identifying A2Badenosine receptor agonists and antagonists as well as methods for using A2Badenosine receptor antagonists to treat cell proliferation orders mediated by the A2Badenosine receptor.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5482856 (1996-01-01), Fell, Jr. et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6440933 (2002-08-01), Bodor et al.
patent: WO 9942093 (1996-12-01), None
patent: WO 9938532 (1999-08-01), None
patent: WO 9942093 (1999-08-01), None
patent: WO 9938532 (1999-09-01), None
patent: WO 9963938 (1999-12-01), None
patent: WO 0051621 (2000-09-01), None
patent: WO 0073307 (2000-12-01), None
Yong-Chul Kim et al., Derivaties of the Triazoloquinazoline Adenosine Antagonist (CGS 15943) Having High Potency at the Human A2B and A3 Receptor Subtypes, J. Med. Chem. 1998, 41, pp. 2835-2845.*
Maria B. Grant et al., Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells, Circulation Research, pp. 699-706, Oct. 15, 1999.*
Anders Kvanta et al., Localization of Adenosine Receptor Messenger RNAs in the Rat Eye, Exp. Eye Res. (1997), 65, pp. 595-602.*
B.K. Kemp et al., Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors, British Journal of Pharmacology (1999) 126, pp. 1796-1800.*
W. Michael Flanagan et al., Cellular penetration and antisense activity by a phenoxazine—substituted heptanculeotide. RESEARCH, pp. 1-5.*
Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23—Feb. 1998, pp. 45-50.*
K. N. Klotz et al., Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells, Naunyn—Schmiedeberg's Arch Pharmacol (1998) 357 pp. 1-9.*
J Lahdenranta et al., Proc. Natl. Acad Sci USA, “An anti-aniogenic state in mice and humans with retinal photoreceptor cell degeneration,” 2001, vol. 98, pp. 10368-10373.*
DDF Ma et al, Biotechnology Annual Review, “Synthetic oligonucleotides as therapeutics: the coming of age,”2000, vol. 5, pp. 155-196.*
S Agrawal et al., Molecular Medicine Today, “Antisense therapeutics: is it as simple as complementary base recognition?” Feb. 2000, vol. 6, pp. 72-81.*
DW Green et al., American College of Surgeons, “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,” Jul. 2000, vol. 191, No. 1, pp. 93-105.*
K-Y Jen et al., Stem Cells, “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” 2000, 18:307-319.*
Y Cao, International Journal of Biochemistry & Cell Biology, “Endogenous angiogenesis inhibitors and their therapeutic implications,” 2001, 33, pp. 357-369.*
Feoktistov et al. Adenosine A2b Receptors evoke Inerleukin-8 Secretion in Human Mast Cells. J. Clin. Invest. vol. 96, Oct. 1995, pp. 1979-1986.*
Yan et al. TGF-B1 Induces Retinal Endothelial Apoptosis. Journal of Cellular Biochemistry. vol. 70, Issue 1, 1998, pp. 70-83.*
Mino, et al., “Adenosine A2βReceptor Inhibition Decreases Retinal Neovascularization in Mice with Oxygen Induced Retinopathy”, IOVS, 2000.
Grant, et al., “Proliferation, Migration and ERK Activation in Human Retinal Endothelial Cells through A2BAdenosine Receptor Stimulation”, Investigative Opthalmology&Visual Science, vol. 42, No. 9, pp. 2068-2073, 2001.
Grant, et al., “Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells”,Circulation Research,pp. 699-706 (1999).
Bailey, (1994)Methods Mol. Biol.32:381-88.
Dean, (1994)Methods Mol. Biol.32:361-79.
Dean, (1998)Methods Mol. Biol.80:23-37.
Dreckhahn et al. (1993)Methods Cell37:7-56.
Gullick, (1994)Methods Mol. Biol.32:289-99.
Jones et al., (1986)Nature321:522.
Kohler & Milstein, (1975),Nature,256:495.
Morrison, (1992)Ann. Rev. Immunol.10:239-65.
Presta, (1992)Curr. Op. Struct. Biol.2:593.
Reichmann et al., (1988)Nature332:323.
Reisner et al., (1998)Trends in Biotechnol.16:242-246.
Spira et al., (1984)J. Immunolog. Meth.74:307.
Steplweski et al., (1985)P.N.A.S. U.S.A.82:8853.
Wright et al., (1992)Crit. Rev. Immunol.12:125-68.
International Search Report for International Application PCT/US02/25713.
B.K. Kemp et al., Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors, British Journal of Pharmacology (1999) 126, pp. 1796-1800.
Belardinelli Luiz
Grant Maria B.
CV Therapeutics Inc.
Lacourciere Karen A.
McDonnell Boehnen & Hulbert & Berghoff LLP
University of Florida Research Foundation
LandOfFree
Method for identifying and using A2B adenosine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying and using A2B adenosine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying and using A2B adenosine receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377785